Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

Author: Yusheng ZHONG (China)

Co-authors: Yong CHENG, Yusheng ZHONG, Jianhong Liang

Purpose

To compare the effectiveness of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP).

Setting/Venue

All infants analysed in the retrospective study were diagnosed as aggressive posterior ROP (APROP) or type 1 ROP were treated with anti-VEGF agents (conbercept or ranibizumab) between July 2012 and March 2018 at the Eye Center in Peking University People’s Hospital and had at least 12 months of follow-up.

Methods

This was a single-centre retrospective study comparing intravitreal conbercept (IVC) and intravitreal ranibizumab (IVR) for the treatment of ROP.In this retrospective study, the date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12 months of follow-up at the Eye Center in People’s Hospital of Peking University were analysed. Regression, progression or recurrence and peripheral retina vascularization were evaluated.This study was approved by the Ethics Committee and Institutional Review Board of Peking University People’s Hospital (Beijing, China). Before treatment, we told the parents of all infants enrolled that using IVR or IVC was off-label, which was an alternative according to the international guidelines for the treatment of ROP.The data were analysed using SPSS.

Results

In total, 283 eyes (145 infants) with conbercept treatment and 916 eyes (480 infants) with ranibizumab treatment were enrolled. In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09%(108/220 eyes) and 28.57% (10/33 eyes), and the recurrence interval was 7.87±0.65 (5.5±9.5) weeks and 10.6 ±1.53 (10.5±13) weeks in the ranibizumab and conbercept groups, respectively. In zone II ROP disease, the recurrence prevalence was 23.56% (164/696 eyes) and 13.31% (33/248 eyes),and the interval of recurrence was 8.40±0.88 (6±10.5) weeks and 11.4±1.35(11±13.5) weeks in the ranibizumab and conbercept groups, respectively. The recurrence prevalence was significantly higher with ranibizumab in Zone I ROP and APROP (p = 0.006) and Zone II ROP (p＜0.001), and the recurrence interval was significantly longer in the conbercept group than that in the ranibizumab (p＜0.001). There was no significant difference in the rate ofretinal vascularization (p = 0.441).

Conlusions

Conbercept and ranibizumab are effective for treating ROP.Compared with ranibizumab, conbercept resulted in less recurrence and longer treatment intervals.

Financial Disclosure

without